Novavax climbs after its Covid jab gets FDA approval
American vaccine maker Novavax rose more than 20% in early trading on Monday after it announced that the Food and Drug Administration fully approved its COVID-19 vaccine, Nuvaxovid.
Nuvaxovid is the only protein-based, non-mRNA Covid vaccine available in the US. It was previously available under emergency use authorization, but the approval by the FDA allows it to stay on the market indefinitely.
The announcement is welcome news for vaccine makers amid worries that Robert F. Kennedy Jr., a vaccine skeptic who now leads the Department of Health and Human Services, would curtail access to vaccines. Moderna, which still makes most of its revenue selling its mRNA-based Covid vaccine, also nudged up on the news.